Cargando…
PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428821/ http://dx.doi.org/10.1097/01.HS9.0000976032.70825.65 |
| _version_ | 1785090562150367232 |
|---|---|
| author | Mutsaers, Pim G. N. J. Abramson, Jeremy S. Namuduri, Manjusha LI, Jingjin Sophos, Nickolas A. Zhu, Min Brouwer-Visser, Jurriaan Mohamed, Hesham Chaudhry, Aafia Davies, Andrew J. |
| author_facet | Mutsaers, Pim G. N. J. Abramson, Jeremy S. Namuduri, Manjusha LI, Jingjin Sophos, Nickolas A. Zhu, Min Brouwer-Visser, Jurriaan Mohamed, Hesham Chaudhry, Aafia Davies, Andrew J. |
| author_sort | Mutsaers, Pim G. N. J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428821 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104288212023-08-17 PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA Mutsaers, Pim G. N. J. Abramson, Jeremy S. Namuduri, Manjusha LI, Jingjin Sophos, Nickolas A. Zhu, Min Brouwer-Visser, Jurriaan Mohamed, Hesham Chaudhry, Aafia Davies, Andrew J. Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428821/ http://dx.doi.org/10.1097/01.HS9.0000976032.70825.65 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Mutsaers, Pim G. N. J. Abramson, Jeremy S. Namuduri, Manjusha LI, Jingjin Sophos, Nickolas A. Zhu, Min Brouwer-Visser, Jurriaan Mohamed, Hesham Chaudhry, Aafia Davies, Andrew J. PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title | PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title_full | PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title_fullStr | PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title_full_unstemmed | PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title_short | PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| title_sort | pb2328: trial in progress: athena-1 – a phase 1 study to assess safety and tolerability of regn5837 in combination with odronextamab in patients with relapsed/refractory aggressive b-cell non-hodgkin lymphoma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428821/ http://dx.doi.org/10.1097/01.HS9.0000976032.70825.65 |
| work_keys_str_mv | AT mutsaerspimgnj pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT abramsonjeremys pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT namudurimanjusha pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT lijingjin pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT sophosnickolasa pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT zhumin pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT brouwervisserjurriaan pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT mohamedhesham pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT chaudhryaafia pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma AT daviesandrewj pb2328trialinprogressathena1aphase1studytoassesssafetyandtolerabilityofregn5837incombinationwithodronextamabinpatientswithrelapsedrefractoryaggressivebcellnonhodgkinlymphoma |